ATE102830T1 - METHOD OF TREATMENT OF INTERSTITIAL BLADDER INFLAMMATION. - Google Patents

METHOD OF TREATMENT OF INTERSTITIAL BLADDER INFLAMMATION.

Info

Publication number
ATE102830T1
ATE102830T1 AT89311177T AT89311177T ATE102830T1 AT E102830 T1 ATE102830 T1 AT E102830T1 AT 89311177 T AT89311177 T AT 89311177T AT 89311177 T AT89311177 T AT 89311177T AT E102830 T1 ATE102830 T1 AT E102830T1
Authority
AT
Austria
Prior art keywords
treatment
bladder inflammation
naltrexone
nalmefene
interstitial bladder
Prior art date
Application number
AT89311177T
Other languages
German (de)
Inventor
Fred P Sherman
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Application granted granted Critical
Publication of ATE102830T1 publication Critical patent/ATE102830T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Threshing Machine Elements (AREA)

Abstract

A method of treating patients suffering from interstitial cystitis comprises daily administration to such patients of from about 1 to about 50 mg of the narcotic antagonists nalmefene or naltrexone. The nalmefene or naltrexone may be administered in equally divided doses from one to four times daily, preferably by the oral route. Parenteral administration may be utilized where suitable.
AT89311177T 1988-11-01 1989-10-30 METHOD OF TREATMENT OF INTERSTITIAL BLADDER INFLAMMATION. ATE102830T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/265,575 US4877791A (en) 1988-11-01 1988-11-01 Method of treatment for interestitial cystitis
EP89311177A EP0367533B1 (en) 1988-11-01 1989-10-30 Method of treatment for interstitial cystitis

Publications (1)

Publication Number Publication Date
ATE102830T1 true ATE102830T1 (en) 1994-04-15

Family

ID=23011021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89311177T ATE102830T1 (en) 1988-11-01 1989-10-30 METHOD OF TREATMENT OF INTERSTITIAL BLADDER INFLAMMATION.

Country Status (11)

Country Link
US (1) US4877791A (en)
EP (1) EP0367533B1 (en)
JP (1) JPH07556B2 (en)
AT (1) ATE102830T1 (en)
AU (1) AU623189B2 (en)
CA (1) CA2001996C (en)
DE (1) DE68913907T2 (en)
DK (1) DK541189A (en)
HK (1) HK119994A (en)
NO (1) NO894295L (en)
ZA (1) ZA897823B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4994466A (en) * 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
EP0820288B1 (en) 1995-03-03 2004-02-11 Endo Pharmaceuticals Inc. Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
EP1150699A4 (en) * 1999-02-01 2004-06-30 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002081477A1 (en) * 2001-03-30 2002-10-17 Toray Industries, Inc. 7-substituted morphinane derivatives and medicinal use thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20070243218A1 (en) * 2006-04-03 2007-10-18 Ellinghuysen Jerry A Stabilized pentosan polysulfate (PPS) formulations and methods of analyzing them
CN105724811A (en) * 2008-12-16 2016-07-06 希尔氏宠物营养品公司 Antioxidant-containing food composition for use in inhibiting histamine pathways in companion animals
WO2019227053A1 (en) * 2018-05-25 2019-11-28 Adamis Pharmaceuticals Corporation Drug compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538186B2 (en) * 1980-03-07 1984-08-02 Scotia Holdings Plc Prostaglandin precursors
WO1987002586A2 (en) * 1985-10-29 1987-05-07 Key Pharmaceuticals, Inc. Method and composition for blocking antigen-induced allergic responses
FR2609632B1 (en) * 1987-01-21 1991-03-29 Shelly Marc NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases

Also Published As

Publication number Publication date
JPH07556B2 (en) 1995-01-11
JPH02188525A (en) 1990-07-24
US4877791A (en) 1989-10-31
AU4385089A (en) 1990-05-10
NO894295L (en) 1990-05-02
CA2001996A1 (en) 1990-05-01
HK119994A (en) 1994-11-11
NO894295D0 (en) 1989-10-27
DK541189D0 (en) 1989-10-30
EP0367533B1 (en) 1994-03-16
CA2001996C (en) 1996-07-23
DE68913907D1 (en) 1994-04-21
ZA897823B (en) 1990-07-25
DE68913907T2 (en) 1994-06-23
DK541189A (en) 1990-05-02
AU623189B2 (en) 1992-05-07
EP0367533A2 (en) 1990-05-09
EP0367533A3 (en) 1991-10-02

Similar Documents

Publication Publication Date Title
ATE107508T1 (en) USE OF NALMEFEN OR NALTREXONE IN THE TREATMENT OF AUTOIMMUNE DISEASES.
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
DE68913907D1 (en) Method of treating interstitial cystitis.
ATE105482T1 (en) TREATMENT OF CANCER WITH SOMATOSTATIN AND ANALOGS THEREOF.
ES2137948T3 (en) ADVANCED SYSTEM OF ADMINISTRATION OF MEDICINES AND METHOD OF TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMACEPINE.
DE69636085D1 (en) Use of gamma-linolenic acid or dihomogammalinolenic acid for the manufacture of a medicament for the treatment of Huntington's chorea
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
ATE213411T1 (en) USE OF PHENSERINE IN THE PRODUCTION OF MEDICATIONS FOR THE TREATMENT OF COGNITIVE DISORDERS
PT97785A (en) METHOD FOR IMPROVING TREATMENT USING, FOR EXAMPLE, DOXAZOSINE
DE69424777D1 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
ATE137965T1 (en) USE OF TOMOXETINE TO TREAT LOWER URINARY TRACT DISORDERS
ATE119770T1 (en) USE OF ACETYL L-CARNITINE FOR THE THERAPEUTIC TREATMENT OF COMA.
ATE78687T1 (en) QUATERNARY DERIVATIVES OF NOROXYMORPHONE FOR THE TREATMENT OF NAUSEA AND VOMITING.
ES2093357T3 (en) ALOPECIA TREATMENT METHOD.
DE69113921D1 (en) Use of a pure opiate antagonist, e.g. Nalmefene, naltrexone, naloxone or diprenorphine, for the treatment of mast cell diseases.
DE68910010D1 (en) Use of dapiprazole in the manufacture of a medicament for preventing tolerance development in analgesic treatment with morphine.
PH30028A (en) Treatment of anxiety in benzodiazepine withdrawn patients
UA30654A (en) Method for treatment of posttraumatic disfunctions of temporomandibular joint
ATE388706T1 (en) THE USE OF WATER-INSOLUBLE S-CAMPTOTHECINE WITH CLOSED LACTONE RING FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF COLON CANCER

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee